RxDoctor Payments Data

Michelle Marcak, APRN

Psychiatric/Mental Health · Mountain Home, ARNPI 1508439456

Payments from drug & device makers

$566in general payments, 2019–2025

Across 30 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$132
  • Alkermes, Inc.$78
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$74
  • Neurocrine Biosciences, Inc.$65
  • Otsuka America Pharmaceutical, Inc.$60
  • Teva Pharmaceuticals USA, Inc.$37
  • plus $120 from 6 others

What the payments were for

  • Food & beverage$51992%
  • Education$478%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$566 in reported general payments places this provider in the 40th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$7,607
Medicare patients
19
Services billed
77

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$125,567
VraylarCariprazine Hcl14$19,218
Lurasidone Hcl19$5,728
Duloxetine Hcl144$4,557
Paliperidone ErPaliperidone14$2,369
Chlorpromazine Hcl12$1,658
Trazodone Hcl138$1,533
Aripiprazole67$1,075
Prazosin Hcl33$1,020
Quetiapine Fumarate79$853
Desvenlafaxine Succinate ErDesvenlafaxine Succinate37$592
Triazolam13$573
Bupropion XlBupropion Hcl49$537
Olanzapine25$467
Bupropion Hcl SrBupropion Hcl37$451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$65$125,56713 claims
AbbVieVraylar$132$19,21814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Mountain Home

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →